Asthma Drugs Market (By Medication: Quick Relief Medications, Long-term Control Medications, Others; By Mode of Administration: Tablets and Capsules, Liquids, Inhalers, Injections, and Sprays and Powders; By Organization Type: Public, Private; By Application: Pediatric, Adults, Adolescent) - Global Market Size, Share, Growth, Trends Analysis, Regional Outlook and Forecasts 2024 - 2033
The global asthma drugs market was estimated at USD 23.93 billion in 2023 and is predicted to reach over USD 39.35 billion by 2033, growing at a CAGR of 5.09% during the forecast period 2024 to 2033.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. asthma drugs market size was estimated at USD 8.36 billion in 2023 and is anticipated to reach around USD 13.76 billion by 2033, growing at a CAGR of 5.11% from 2024 to 2033.
The research report deals with the industry prospects of asthma drugs products around regions including Europe, North America, Latin America, Asia-Pacific, and Middle East and Africa. Asthma Drugs market is taken by North America owing to increasing numbers of patients suffering from the asthma diseases, advanced healthcare infrastructure, favorable government policies, and growing ageing population U.S. of the North America. Addition to this, presence of leading players in the region along with strategies that are implemented by the major players in the countries of North America is expected to witness substantial growth in the target industry in the near future. Asia Pacific is likely to list the noteworthy CAGR, on account of growth in the demand for the asthma drugs in emerging economies owing growing prevalence. Also, most of the key players operating in the industry are investing heavily in order to get the competitive edge in the asthma drugs market in Asia Pacific. Further, the Latin America as well as Middle East and Africa regions will likely to register moderate growth in the coming.
Crucial factors accountable for market growth are:
Increasing prevalence of asthma and growth in the old age population are driving factors for the growth of asthma market. Ongoing R&D activities and technological advancements can create lucrative growth opportunities for the key players operating in the global asthma drugs market. High costs associated with the research and development of the asthma drugs is key factor hampering growth of the global market. Key players operating in the target market are focusing on the technological advancements as well as research and developments in order to produce low cost drugs. Increasing launches of pipeline drugs and strategic developments by the major players are creating numerous growth prospects in the target industry.
COVID-19 Impact on Global Asthma Drugs Market
The COVID-19 impacted commercials market areas across the globe, but asthma drug industry is an exception. Since, COVID-19 as well as asthma are nothing but the respiratory diseases, the demand for the asthma treatment is increasing which in turn boosting growth of the target market. Also, asthma is deliberated as common chronic disease. Increased patient pool is expected to create need for asthma drugs. However, because of COVID-19, target market faced certain unexpected things like raw materials price volatility, uncertainty of the supply chain, insufficient manpower in the production facility worldwide. However, after the launch of covid vaccine, companies are coming back to their original position by resuming to the work with greater speed.
Foremost players of the global asthma drugs industry are focusing on the strategic partnerships similar acquisitions, mergers in order to enhance their position in the global market and to get the comparative edge. Further companies are launching advanced products in order to fulfill the customized demands of the end-users. These trends are anticipated to continue and will fuel growth of target market over the forecast time-frame. Growing use of asthma drugs for the effective treatment for COVID-19 is key trend witnessed in the target market, this trend is anticipated to continue and will boost growth of this industry in the near future. Asthma drugs that are used to help prevent the symptoms of asthma, are being touted as the silver bullet for COVID-19. Asthma drugs reduce severity of asthma attack by preventing inflammation in the lungs and can be inhaled directly to the lungs using a nebulizer. As the COVID-19 and asthma are respiratory illnesses, most of the end-user is also using asthma inhalers for treatment of COVID-19.
Report Highlights | Details |
Market Size in 2023 | USD 23.93 Billion |
Market Size by 2033 | USD 39.35 Billion |
Growth Rate From 2022 to 2030 | CAGR of 5.09% |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | Medication, Mode of Administration, Organization Type, Application |
Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
Companies Mentioned | GlaxoSmithKline, Pfizer, Vectura Group, Boehringer Ingelheim, Roche, Novartis, Merck, AstraZeneca, Teva Pharmaceutical |
The quick relief medications segment held the largest share of the asthma drugs market in 2023. Quick relief medications, such as short-acting beta-agonists (SABAs) like albuterol, provide rapid relief from asthma symptoms such as wheezing, chest tightness, and shortness of breath. Their fast-acting nature makes them essential for managing acute asthma attacks. Quick relief medications are often recommended as the first-line treatment for acute asthma symptoms and exacerbations. They are the go-to medications during asthma attacks to provide immediate relief and prevent worsening of symptoms.
The inhalers segment held the largest share of the asthma drugs market in 2023 and the segment is observed to sustain the position throughout the forecast period. Inhalers are compact, portable, and easy to use, making them convenient for asthma patients to carry with them wherever they go. This allows patients to have quick access to their medication whenever they experience symptoms or asthma exacerbations. Inhalers deliver medication directly to the lungs, bypassing the digestive system and minimizing systemic side effects commonly associated with oral medications. This targeted delivery helps to reduce the risk of adverse reactions and improves the safety profile of asthma drugs.
The public segment led the asthma drugs market in 2023. Public organizations are responsible for managing healthcare infrastructure, including hospitals, clinics, and public health programs. They ensure the availability and accessibility of asthma drugs to patients through government-funded healthcare services and distribution networks. Public organizations collaborate with pharmaceutical companies, academic institutions, and research organizations to conduct clinical trials, advance scientific research, and develop innovative asthma treatments. These collaborative efforts drive drug discovery and development in the asthma therapeutics market.
The adults segment dominated the asthma drugs market in 2023. Asthma is a chronic respiratory condition that often persists into adulthood. The prevalence of asthma tends to be higher among adults compared to children, leading to a larger patient population in the adult segment. As the global population ages, the proportion of adults with asthma is increasing. Older adults may develop asthma later in life or have existing asthma that requires ongoing management with medication.
Major Market Segments Covered:
By Medication
By Mode of Administration
By Organization Type
By Application
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Asthma Drugs Market Market
5.1. COVID-19 Landscape: Asthma Drugs Market Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Asthma Drugs Market Market, By Medication
8.1. Asthma Drugs Market Market Revenue and Volume Forecast, by Medication, 2024-2033
8.1.1. Quick Relief Medications
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Long-term Control Medications
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Others
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Asthma Drugs Market Market, By Mode of Administration
9.1. Asthma Drugs Market Market Revenue and Volume Forecast, by Mode of Administration, 2024-2033
9.1.1. Tablets and Capsules
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Liquids
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Inhalers
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
9.1.4. Injections
9.1.4.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Asthma Drugs Market Market, By Organization Type
10.1. Asthma Drugs Market Market Revenue and Volume Forecast, by Organization Type, 2024-2033
10.1.1. Public
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Private
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Asthma Drugs Market Market, By Application
11.1. Asthma Drugs Market Market Revenue and Volume Forecast, by Application, 2024-2033
11.1.1. Pediatric
11.1.1.1. Market Revenue and Volume Forecast (2021-2033)
11.1.2. Adults
11.1.2.1. Market Revenue and Volume Forecast (2021-2033)
11.1.3. Adolescent
11.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 12. Global Asthma Drugs Market Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.1.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.1.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.1.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.1.5.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.1.5.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.1.5.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.1.6.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.1.6.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.1.6.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.2.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.2.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.2.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.2.5.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.2.5.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.2.5.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.2.6.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.2.6.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.2.6.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.2.7.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.2.7.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.2.7.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.2.8.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.2.8.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.2.8.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.3.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.3.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.3.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.3.5.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.3.5.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.3.5.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.3.6.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.3.6.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.3.6.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.3.7.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.3.7.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.3.7.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.3.8.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.3.8.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.3.8.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.4.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.4.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.4.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.4.5.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.4.5.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.4.5.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.4.6.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.4.6.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.4.6.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.4.7.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.4.7.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.4.7.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.4.8.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.4.8.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.4.8.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.5.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.5.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.5.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.5.5.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.5.5.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.5.5.4. Market Revenue and Volume Forecast, by Application (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Medication (2021-2033)
12.5.6.2. Market Revenue and Volume Forecast, by Mode of Administration (2021-2033)
12.5.6.3. Market Revenue and Volume Forecast, by Organization Type (2021-2033)
12.5.6.4. Market Revenue and Volume Forecast, by Application (2021-2033)
Chapter 13. Company Profiles
13.1. GlaxoSmithKline
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Pfizer
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Vectura Group
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Boehringer Ingelheim
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Roche
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Novartis
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. AstraZeneca
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Teva Pharmaceutical
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client